Improved preventative care for diabetes has cut the rate of serious complications such as heart attack and stroke over the past 20 years in the U.S. while the number Americans diagnosed with the disease continues to rise, a government report found.
Takeda Pharmaceutical Co. and Eli Lilly & Co. were ordered to pay a combined $9 billion in punitive damages after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.
MannKind Corp.’s inhaled diabetes treatment won the backing of a U.S. advisory panel, moving the company another step closer in its long-running effort get its first product on the market. The shares rose 74 percent.
Weight-loss surgery may be a better way to treat diabetes than traditional drug therapy alone, according to a study that found the operation was more likely to keep the chronic condition at bay for at least three years.
MannKind Corp.’s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said.
A European Medicines Agency panel recommended approving a diabetes drug from Boehringer Ingelheim GmbH and Eli Lilly & Co. that was rejected this month in the U.S. because of manufacturing deficiencies.
Scientists have uncovered gene mutations that slash the risk of Type 2 diabetes regardless of age and weight, offering drugmakers a novel target to combat one of the major health threats confronting the modern world.
Eli Lilly & Co.’s experimental drug dulaglutide was as good at controlling Type 2 diabetes as the leading treatment in a clinical trial, providing Lilly with a potential marketing advantage as it seeks to gain approval of the medicine.